Emerging targets for therapeutic development in diabetes and its complications: The RAGE signaling pathway

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 2, 2015, Pages 135-144

  Litwinoff, E M S ^a   Hurtado Del Pozo, C ^a   Ramasamy, R ^a   Schmidt, A M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIAPH1 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; IMMUNOGLOBULIN RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC OBESITY; DIABETIC RETINOPATHY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; WOUND HEALING IMPAIRMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR TARGETED THERAPY; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84962207552     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.148     Document Type: Article

References (78)

1. WHO. Obesity and Overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ (2015). Accessed 9 February 2015
2. CDC. Adult Obesity Facts. http://www.cdc.gov/obesity/data/adult.html (2014). Accessed 9 February 2015
3. CDC. National Diabetes Statistics Report. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf (2014
4. Alberti, K.G., & Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 15, 539-553 (1998
5. Gaens, K.H., Stehouwer, C.D., & Schalkwijk, C.G. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. Curr. Opin. Lipidol. 24, 4-11 (2013
6. Schmidt, A.M., Hori, O., Brett, J., Yan, S.D., Wautier, J.L., & Stern, D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14, 1521-1528 (1994
7. Wu, C.H., Huang, S.M., Lin, J.A., & Yen, G.C. Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct. 2, 224-234 (2011
8. Goldin, A., Beckman, J.A., Schmidt, A.M., & Creager, M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597-605 (2006
9. Schmidt, A.M., Yan, S.D., Yan, S.F., & Stern, D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955 (2001
10. Rogge, M.M. The role of impaired mitochondrial lipid oxidation in obesity. Biol. Res. Nurs. 10, 356-373 (2009
11. Song, F., et al. RAGE regulates themetabolic and inflammatory response to high-fat feeding inmice. Diabetes 63, 1948-1965 (2014
12. Schmidt, A.M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267, 14987-14997 (1992
13. Brett, J., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143, 1699-1712 (1993
14. Demling, N., Ehrhardt, C., Kasper, M., Laue, M., Knels, L., & Rieber, E.P. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 323, 475-488 (2006
15. Taguchi, A., et al. Blockade of RAGE-Amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354-360 (2000
16. Hofmann, M.A., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901 (1999
17. Yan, S.D., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimers disease. Nature 382, 685-691 (1996
18. Rai, V., et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J. Exp. Med. 209, 2339-2350 (2012
19. Chavakis, T., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198, 1507-1515 (2003
20. Hudson, B.I., et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 283, 34457-34468 (2008
21. Wallar, B.J., & Alberts, A.S. The formins: active scaffolds that remodel the cytoskeleton. Trends Cell Biol. 13, 435-46 (2003
22. Kuhn, S., & Geyer, M. Formins as effector proteins of Rho GTPases. Small GTPases 5, e29513 (2014
23. Thumkeo, D.,Watanabe, S., & Narumiya, S. Physiological roles of Rho and Rho effectors inmammals. Eur. J. Cell Biol. 92, 303-315 (2013
24. Lopez-Diez, R., Rastrojo, A., Villate, O., & Aguado, B. Complex tissuespecific patterns and distribution of multiple RAGE splice variants in different mammals. Genome Biol. Evol. 5, 2420-2435 (2013
25. Tam, X.H., Shiu, S.W., Leng, L., Bucala, R., Betteridge, D.J., & Tan, K.C. Enhanced expression of receptor for advanced glycation endproducts is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin. Sci. (Lond) 120, 81-89 (2011
26. Koyama, H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 2587-2593 (2005
27. Geroldi, D., Falcone, C., & Emanuele, E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13, 1971-1978 (2006
28. Cheng, D.T., et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 188, 948-957 (2013
29. Gaens, K.H., et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J. Clin. Endocrinol. Metab. 94, 5174-5180 (2009
30. Prevost, G., et al. Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab. 31, 35-39 (2005
31. Ramprasad, S., Radha, V., Mathias, R.A., Majumder, P.P., Rao, M.R., & Rema, M. Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India. Eye (Lond 21, 395-401 (2007
32. Balasubbu, S., et al. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med. Genet. 11, 158 (2010
33. Park, S.Y., Kim, Y.A., Hong, Y.H., Moon, M.K., Koo, B.K., & Kim, T.W. Up-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy. J. Clin. Neurol. 10, 334-341 (2014
34. Bierhaus, A., et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest. 114, 1741-1751 (2004
35. Juranek, J.K., et al. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes 62, 931-943 (2013
36. McVicar, C.M., et al. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia 58, 1129-1137 (2015
37. Reiniger, N., et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 59, 2043-2054 (2010
38. Boudina, S., & Abel, E.D. Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 11, 31-39 (2010
39. Hutchinson, K.R., Lord, C.K., West, T.A., & Stewart, J.A., Jr. Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes. PloS One 8, e72080 (2013
40. Yan, D., et al. Effects of advanced glycation end products on calcium handling in cardiomyocytes. Cardiology 129, 75-83 (2014
41. Soro-Paavonen, A., et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57, 2461-2469 (2008
42. Bu, D.X., et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ. Res. 106, 1040-1051 2010
43. Tian, M., et al. The relationship between inflammation and impaired wound healing in a diabetic rat burn model. J. Burn Care Res. e-pub ahead of print 2014
44. Nadatani, Y., et al. High-mobility group box 1 inhibits gastric ulcer healing through Toll-like receptor 4 and receptor for advanced glycation end products. PloS One 8, e80130 (2013
45. Brix, J.M., Hollerl, F., Kopp, H.P., Schernthaner, G.H., & Schernthaner, G. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Int. J. Obes. (Lond) 36, 1412-1417 (2012
46. Norata, G.D., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr. Metab. Cardiovasc. Dis. NMCD 19, 129-134 (2009
47. Tan, K.C., et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50, 1819-1825 (2007
48. Hudson, B.I., et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 216, 192-198 (2011
49. Falcone, C., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25, 1032-1037 (2005
50. Santilli, F., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 43, 1255-1262 (2007
51. Emanuele, E., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62, 1734-1736 (2005
52. Wang, L.J., Lu, L., Zhang, F.R., Chen, Q.J., De Caterina, R., & Shen, W.F. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur. J. Heart Fail. 13, 440-449 (2011
53. Prasad, K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int. J. Angiol. 23, 11-16 (2014
54. Colhoun, H.M., et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 60, 2379-2385 (2011
55. Vazzana, N., Santilli, F., Cuccurullo, C., & Davi, G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med. 4, 389-401 (2009
56. Piarulli, F., Sartore, G., & Lapolla, A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol. 50, 101-110 (2013
57. Yanagisawa, K., et al. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Diabetes Metab. Res. Rev. 30, 693-700 (2014
58. Koyama, H., et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). Atherosclerosis 234, 329-334 (2014
59. Amin, M.N., Mosa, A.A., & El-Shishtawy, M.M. Clinical study of advanced glycation end products in ogyptian diabetic obese and nonobese patients. Int. J. Biomed. Sci. IJBS 7, 191-200 (2011
60. Park, L., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025-1031 (1998
61. Lee, D., et al. The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice. PloS One 8, e69669 (2013
62. Bucciarelli, L.G., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835 (2002
63. Marsche, G., Weigle, B., Sattler, W., & Malle, E. Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J. 21, 3075-3082 (2007
64. Wear-Maggitti, K., Lee, J., Conejero, A., Schmidt, A.M., Grant, R., & Breitbart, A. Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation. Ann. Plast. Surg. 52, 519-521; discussion 22 (2004
65. Goova, M.T., et al. Blockade of receptor for advanced glycation endproducts restores effective wound healing in diabetic mice. Am. J. Pathol. 159, 513-525 (2001
66. Wendt, T.M., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137 (2003
67. Moore, T.C., et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest. Ophthalmol. Visual Sci. 44, 4457-4464 (2003
68. Gaens, K.H., et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesityinduced dysregulation of adipokine expression and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 34, 1199-1208 (2014
69. Rai, V., et al. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-Terminal rage (ctRAGE) and its binding to mDia1. J. Biol. Chem. 287, 5133-5144 (2012
70. Toure, F., et al. Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ. Res. 110, 1279-1293 (2012
71. Xu, Y., et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 285, 23233-23240 (2010
72. Bianchi, R., Kastrisianaki, E., Giambanco, I., & Donato, R. S100B protein stimulates microglia migration via RAGE-dependent upregulation of chemokine expression and release. J. Biol. Chem. 286, 7214-7226 (2011
73. Sahai, E., & Marshall, C.J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 4, 408-415 (2002
74. Jensen, L.J., Denner, L., Schrijvers, B.F., Tilton, R.G., Rasch, R., & Flyvbjerg, A. Renal effects of a neutralising RAGE-Antibody in longterm streptozotocin-diabetic mice. J. Endocrinol. 188, 493-501 (2006
75. Reverdatto, S., Rai, V., Xue, J., Burz, D.S., Schmidt, A.M., & Shekhtman, A. Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells. PloS One 8, e65180 (2013
76. Chen, Y., et al. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181, 4272-4278 (2008
77. Deane, R., et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, 1377-1392 (2012
78. Ku, S.H., et al. Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. Arch. Pharm. Res.; e-pub ahead of print 2015.